Agfa-Gevaert shares fall to €0.3655, a record low after its results
The stock hits a new all-time intraday low, a few hours after publishing its third-quarter results. Medical imaging holds up, but the advanced materials division weighs on the group's profitability.
A record low at €0.3655 and a share price below all its averages
Agfa-Gevaert shares fall 5.54% to €0.375 intraday, after touching €0.3655. The previous all-time low, €0.3660, dated from 29 July.
The stock has broken below its previous support at €0.39, which has now become resistance. It trades below its three moving averages, 6.25% below its MA20 and 14.77% below its MA200, and has lost more than 54% over one year. The RSI at 37 remains in neutral territory, with no oversold signal at this stage.
Adjusted EBITDA falls to €1 million in the third quarter, HealthCare IT holds firm
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Agfa-Gevaert published its third-quarter results this morning. On continuing operations, adjusted EBITDA declined 63.9%, from €4 million to €1 million, while it rose 18% over nine months, to €25 million.
Revenue remains stable at €210 million, but the two divisions diverge: HealthCare IT improves its profitability and its recurring revenue grows 10.9%, while Imaging and Advanced Materials, which accounts for the bulk of sales, swings to negative adjusted EBITDA.
The group also indicates that its 2026 free cash flow will be more negative than in 2025, despite €64 million of annual savings already achieved.
SectorDispositifs médicaux et optique›Dispositifs médicaux / imagerie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 631 millions d'euros
Quarterly revenue: 631 millions d'euros
Revenue growth: -2,5 %
EBITDA: 25 millions d'euros
EBITDA margin: 4 %
Net income: -51 millions d'euros
Free cash flow: -76 millions d'euros
92 millions d'euros
Guidance from the release
Vrije kasstroom over volledige jaar 2026 zal naar verwachting negatiever uitvallen dan 2025 ondanks besparingen
Risks mentioned
Green Hydrogen Solutions volume daalde 82,2% in Q3 2026 door zwakke markt en RED III implementatieverlagingen
Digital Radiology Solutions omzet daalde 8,4%; Digital Printing Solutions daalde 10,2% in Q3
Filmproducten volumedaling blijft aanhouden, vooral in China
Opportunities identified
HealthCare IT order intake 12-maands lopend groeide 21% tot 197 miljoen euro met cloudbestellingen meer dan verdrievoudigd
Recurrente omzet HealthCare IT steeg 10,9% en staat nu voor 69% van totale omzet in Q3 2026
Besparingsprogramma's hebben 64 miljoen euro jaarlijkse besparing gerealiseerd eind Q3 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
